CompletedNot Applicable

Outcomes Of The Spanish Cohort Of Early Access To Pertuzumab And Trastuzumab Emtansine

Spain220 participantsStarted 2017-12-01

Plain-language summary

The overall study objective is to evaluate the effectiveness and safety of Trastuzumab emtansine (T-DM1) and Pertuzumab under real-world disease conditions in the Spain, and specifically in patients treated under compassionate use or early access program

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients (age ≥ 18 years at enrolment) with HER2-positive metastatic or locally recurrent unresectable breast cancer and who are treated with Trastuzumab emtansine (T-DM1) or Pertuzumab. * Patients who initiate Trastuzumab emtansine (T-DM1) and Pertuzumab under Spanish compassionate use or early access program. Exclusion Criteria: * Given the characteristics of the study there are no exclusion criteria.

What they're measuring

Overall survival.

Timeframe: Through study completion (from date of start of treatment until the date of death from any cause, assessed up to 48 months).

Trial details

NCT IDNCT03025711

SponsorBELEN RUIZ-ANTORAN

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-10-01

View on ClinicalTrials.gov More Breast Neoplasms trials